# Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer

> **NCT07125924** · NA · NOT_YET_RECRUITING · sponsor: **National Cancer Center, Korea** · enrollment: 54 (estimated)

## Conditions studied

- Bladder Cancer
- Radiation Cystitis

## Interventions

- **DEVICE:** Blad-Care (sodium hyaluronate 1.6%, 800 mg/50 mL, BioPlus Co., Ltd.)
- **OTHER:** Normal Saline (NS)

## Key facts

- **NCT ID:** NCT07125924
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-22
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07125924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07125924, "Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT07125924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*